Navigation Links
Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc.

SAN FRANCISCO, July 31 /PRNewswire-USNewswire/ -- The Addario Lung Cancer Medical Institute (ALCMI) today announced the execution of a letter of intent (LOI) to collaborate with Response Genetics, Inc. (Nasdaq: RGDX) on molecular diagnostic testing and banking of advanced-stage Lung Cancer tissues.


Specific molecular features of tumors, including EGFR mutations, ras mutations, ERCC1, RRM1 or TS overexpression, have been shown in multiple studies to have prognostic importance and/or be associated with benefit from specific interventions, as described in the NCCN 2009 Clinical Practice Guidelines in Oncology. Currently, only a minority of patients with Lung Cancer, especially advanced stage disease, are having these molecular assessments performed. As a result of ALCMI's efforts to address this inequity, RGI will employ its panel of clinically-validated genetic tests -- ResponseDX: Lung(TM) -- and rapidly communicate the results with the patients' physicians. "We are thrilled to collaborate with Response Genetics, and as a Lung Cancer survivor I know first-hand just how critical these tests will be to bringing the right therapies to each patient in a time-sensitive manner," said Bonnie J. Addario, founder of ALCMI and the Bonnie J. Addario Lung Cancer Foundation.

"We are extremely pleased to be working with ALCMI to help make personalized medicine a reality for Lung Cancer patients," said Kathleen Danenberg, Response Genetics' president and CEO.

The lack of biospecimens from Lung Cancer patients with advanced disease is a major hurdle to advancing the state-of-the-art in applying individual tumor characteristics to the real-world management of patients. In response to this systematic barrier to progress, ALCMI is now poised to launch a targeted, multi-institutional tissue bank, the CASTLE Network. Under the terms of the LOI, this tissue bank which will be housed at Response Genetics' Los Angeles laboratory facility. "ALCMI's CASTLE Network will be the only resource of its kind in Lung Cancer that facilitates the collection of biospecimens from advanced-stage patients," said Steven Young, president and COO of ALCMI.

"Coupled with the routine determination of a panel of documented, clinically-significant biomarkers by Response Genetics, the ALCMI CASTLE Network will help lead the way as the Lung Cancer research community's premier, open access source for high quality proteomics, genomics, target validation, and correlative science analyses," said David Carbone, M.D., Ph.D., Vanderbilt University, and chair of ALCMI's Scientific Leadership Board.

About Lung Cancer

According to the National Cancer Institute, estimated new cases and deaths related to Lung Cancer for 2008 is: New cases 215,020, and Deaths: 161, 840. Lung Cancer causes 30% of all cancer deaths according to the American Cancer Society. Lung Cancer is the leading cause of cancer death in both men and women and in every ethnic group. Lung cancer kills more people than breast, prostate, colon, liver, melanoma and kidney cancers combined.


Concerned by the continued lack of meaningful progress against Lung Cancer, in 2006-2007 the Bonnie J. Addario Lung Cancer Foundation assembled the field's foremost researchers, clinicians, and business leaders from academic and community medical centers, biopharmaceutical companies, and the investment community in order to ask a fundamental question: "If money for research and development was not a barrier, and a true collaboration could be achieved, what would you require to achieve a cure for Lung Cancer in the least amount of time?"

The overwhelming consensus response was to establish a national, virtual Lung Cancer institute -- an honest third-party broker that would develop and direct high-quality tissue specimen repositories, data systems, and fostered collaborations. As a result, Lung Cancer survivor Bonnie J. Addario and her husband Tony Addario established ALCMI in early 2008 as a 501(c)(3) non-profit organization, with Mr. Steven Young assuming the role of President and Chief Operating Officer in the third quarter of that year.

Mission Statement:

The Addario Lung Cancer Medical Institute is dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for Lung Cancer patients. Over 450 people die a day of Lung Cancer in the United States and 1.3 million annually worldwide. Lung Cancer surpassed breast cancer as the number one killer of women in 1987. Sixty percent of Lung Caner is now diagnosed in NEVER smokers and former smokers and it kills more people than breast, prostate, colon, liver, melanoma and kidney cancers combined.

ALCMI's Scientific Leadership Board:

David Carbone, M.D., Ph.D., (Vanderbilt University), David Gandara, M.D., (University of California, Davis), David Jablons, M.D., (University of California, San Francisco), Pasi Janne, M.D., Ph.D., (Dana-Farber Cancer Institute), Ite Laird-Offringa, Ph.D., (University of Southern California), Harvey Pass, M.D., (New York University) and Rafael Rosell, M.D., Ph.D., (Catalan Institute of Oncology, Spain).

ALCMI is currently in negotiations with several community medical centers, thus further expanding the breadth, depth and diversity of ALCMI's Lung Cancer patient populations, while also preparing to launch its Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network in the fall of 2009.

    Media Relations Contact:
    Sheila Von Driska

    For more information, contact Mr. Steven Young at or
    (203) 226-5765.

SOURCE Bonnie J. Addario Lung Cancer Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Joan Gaeta Lung Cancer Foundation Donates $15,000 to Addario Lung Cancer Medical Institute (ALCMI) for Lung Cancer Research
2. Hope for Lung Cancer Research Dollars in California: The Bonnie J. Addario Lung Cancer Foundation (BJALCF) Applauds Landmark Legislation to Push through Funding for Lung Cancer Research in California
3. AIDS patients face higher risk of HPV-related cancers as immunosuppression grows
4. Breast CT Scanner Could Improve Cancer Screen Comfort
5. Cancer treatment controls macular edema related to diabetes and to cataract surgery
6. Lung Cancer Alliance Launches Online Early Interventions Resource Center
7. Virus May Affect Survival in Head and Neck Cancer
8. Cancer Survivors Face Tough Road Long After Treatment Ends
9. Texas on Top of Cancer Research: Dallas Regional Chamber Hosts Forum on New $3 Billion Fund
10. Brain Scan May Help Predict Cancer Drug Response
11. Living Green Marketplace Announces the Cancer Care Wellness Box to Bring Comfort to Cancer Patients During Medical Treatment
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... In an article ... variables that determine which patients are or are not eligible for bariatric surgery. The ... BMI over 40, are more than 100 pounds overweight, or have a BMI of ...
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to five seconds to ... that the first impression be positive and reflects business values. If a client starts ... or want to return. They will also share their thoughts about a business with ...
(Date:11/24/2015)... ... 24, 2015 , ... Cancer patients, survivors, caregivers, family members ... live taping of the next CURE Connections® video series on Saturday, ... Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the Ron Foley ... to yield insights into how to detect and treat pancreatic cancer (PC). , ... small, non-coding RNA molecules (ncRNA), genetic material that is present in the blood of ...
(Date:11/24/2015)... ... 24, 2015 , ... Sir Grout of Baltimore is proud ... The award recognizes good companies for excellence in service and a commitment to ... hard surface restoration company earned this recognition after a thorough review by the ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 2015 Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide, announced ... will present at the 27 th Annual Piper ... 11:30 a.m. ET. The conference will be held at ... York City . Abaxis, Inc. is ...
(Date:11/24/2015)... , Nov. 24, 2015  Eyewear brand Revo ... with U2 lead singer and activist Bono as part of ... vision impairment and blindness in more than 5 million people ... Revo will donate $10 from the sale of every pair ... to a total of $10 million to the "Buy Vision, ...
(Date:11/24/2015)... , Nov. 24, 2015   Mast Therapeutics, Inc. ... its molecular adhesion and sealant technology (MAST) platform to ... and stroke, today announced that the Company,s Chief Executive ... the Piper Jaffray 27 th Annual Healthcare Conference ... at the New York Palace hotel in ...
Breaking Medicine Technology: